DAE HWA Pharmaceutical Co. Ltd (067080) - Cash Flow Conversion Efficiency
Based on the latest financial reports, DAE HWA Pharmaceutical Co. Ltd (067080) has a cash flow conversion efficiency ratio of 0.026x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩2.06 Billion ≈ $1.40 Million USD) by net assets (₩79.14 Billion ≈ $53.63 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
DAE HWA Pharmaceutical Co. Ltd - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how DAE HWA Pharmaceutical Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 067080 liabilities breakdown for a breakdown of total debt and financial obligations.
DAE HWA Pharmaceutical Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of DAE HWA Pharmaceutical Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Universal Microelectronics Co Ltd
TW:2413
|
0.141x |
|
Deutsche Konsum REIT AG
XETRA:DKG
|
0.035x |
|
Caribou Biosciences Inc
NASDAQ:CRBU
|
-0.170x |
|
Daesung Ind
KO:128820
|
0.000x |
|
Elanders AB (publ)
ST:ELAN-B
|
0.064x |
|
Ellington Residential Mortgage
NYSE:EARN
|
0.041x |
|
IM Vinaria Purcari SRL
RO:WINE
|
-0.002x |
|
KPX Chemical
KO:025000
|
0.013x |
Annual Cash Flow Conversion Efficiency for DAE HWA Pharmaceutical Co. Ltd (2011–2025)
The table below shows the annual cash flow conversion efficiency of DAE HWA Pharmaceutical Co. Ltd from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see 067080 company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩79.14 Billion ≈ $53.63 Million |
₩5.43 Billion ≈ $3.68 Million |
0.069x | -19.40% |
| 2024-12-31 | ₩72.00 Billion ≈ $48.79 Million |
₩6.13 Billion ≈ $4.15 Million |
0.085x | +1155.66% |
| 2023-12-31 | ₩73.23 Billion ≈ $49.63 Million |
₩-590.27 Million ≈ $-400.02K |
-0.008x | -107.81% |
| 2022-12-31 | ₩77.99 Billion ≈ $52.85 Million |
₩8.05 Billion ≈ $5.45 Million |
0.103x | -21.32% |
| 2021-12-31 | ₩79.67 Billion ≈ $53.99 Million |
₩10.45 Billion ≈ $7.08 Million |
0.131x | +270.58% |
| 2020-12-31 | ₩81.98 Billion ≈ $55.56 Million |
₩2.90 Billion ≈ $1.97 Million |
0.035x | +6935.37% |
| 2019-12-31 | ₩79.35 Billion ≈ $53.77 Million |
₩-41.07 Million ≈ $-27.83K |
-0.001x | -100.38% |
| 2018-12-31 | ₩76.88 Billion ≈ $52.10 Million |
₩10.49 Billion ≈ $7.11 Million |
0.136x | -4.30% |
| 2017-12-31 | ₩76.75 Billion ≈ $52.02 Million |
₩10.94 Billion ≈ $7.42 Million |
0.143x | +7.31% |
| 2016-12-31 | ₩66.15 Billion ≈ $44.83 Million |
₩8.79 Billion ≈ $5.96 Million |
0.133x | +233.71% |
| 2015-12-31 | ₩61.06 Billion ≈ $41.38 Million |
₩2.43 Billion ≈ $1.65 Million |
0.040x | -62.31% |
| 2014-12-31 | ₩58.51 Billion ≈ $39.65 Million |
₩6.18 Billion ≈ $4.19 Million |
0.106x | -51.73% |
| 2013-12-31 | ₩62.03 Billion ≈ $42.04 Million |
₩13.57 Billion ≈ $9.20 Million |
0.219x | +132.79% |
| 2012-12-31 | ₩61.39 Billion ≈ $41.60 Million |
₩5.77 Billion ≈ $3.91 Million |
0.094x | +56.14% |
| 2011-12-31 | ₩56.99 Billion ≈ $38.62 Million |
₩3.43 Billion ≈ $2.32 Million |
0.060x | -- |
About DAE HWA Pharmaceutical Co. Ltd
DAE HWA Pharmaceutical Co., Ltd., a pharmaceutical company, produces and supplies pharmaceutical products in South Korea. The company offers drugs for anticancer, antibiotics, antifungal and skin ailment, antivirus, anti-allergosis, hemorrhoids, antidepressant, antiepileptic, psychotropic agent, anti respiratory, anti-inflammatory, analgesic, skeletal muscle relaxants, osteoporosis, anti-arthriti… Read more